Abstract
Objective: The increase in resistant Gram-negative bacteria is a major concern and has led to difficulties in the treatment of infections. The aim of this study was to compare the in vitro efficacy of CLZ-TAZ and CAZ-AVB combinations against carbapenem-resistant Enterobacteriaceae strains.
 
 Methods: 80 carbapenem-resistant Enterobacteriaceae species isolated from various samples sent to our laboratory were included in the study. Identification and antimicrobial susceptibility of strains were performed using automated systems. The presence of carbapenemases in all isolates was tested using the CarbaNP test and the carbapenem inactivation method. The presence of carbapenemase genes was tested by multiplex PCR.
 
 Results: The presence of carbapenemases was detected in 60 % E. coli isolates and in 78.5% K. pneumoniae isolates via phenotypic tests. OXA-48 enzyme was found in 73.7% of isolates containing carbapenemase. The second most common enzyme was NDM.The assessment of the efficacy of the β-lactam/β-lactamase inhibitor combinations against CRE isolates revealed that the activity of CAZ-AVB (77%) was higher than CLZ-TAZ (48%).
 
 Conclusion: Our findings suggest that CAZ-AVB and CLZ-TAZ may be promising in the treatment of infections caused by CRE strains. Sensitivity rates were higher with ceftazidime-avibactam than with ceftolozane-tazobactam. The data obtained in this study will contribute to the clinical use of these agents in our country.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
